{"disease":{"id":"ad","name":"ad"},"drugs":{"marketed":[{"drug_id":"pembrolizumab","indication_name":"NSCLC (neoadjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"NSCLC (adjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (MIBC, neoadjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"NSCLC (neoadjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"NSCLC (adjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (MIBC, neoadjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"abrilada","indication_name":"Hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"nivolumab","indication_name":"Postoperative adjuvant therapy for urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Unresectable, advanced or recurrent gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or functional or anatomical asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 50 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with functional or anatomical asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 65 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-20","indication_name":"Active immunisation in infants, children, and adolescents (6 weeks to <18 years)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"},{"drug_id":"prevnar-20","indication_name":"Prevention of pneumococcal pneumonia in adults (18+)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"},{"drug_id":"prevnar-20","indication_name":"Prevention of invasive pneumococcal disease in adults (18+)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"},{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, in combination with pemetrexed and platinum-based chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"upadacitinib","indication_name":"Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"onabotulinumtoxina","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Giant cell arteritis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active ankylosing spondylitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Non-radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"shingrix","indication_name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Shingrix","generic_name":"shingrix","company_name":"GSK","drug_phase":"marketed","molecular_target":"Varicella zoster virus","drug_class":"Vaccine","quality_score":48,"revenue":"4300","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"secukinumab","indication_name":"Non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosentyx","generic_name":"secukinumab","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Interleukin-17A (IL-17A)","drug_class":"IL-17A antagonist","quality_score":10,"revenue":"3900","mechanism":"Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"lee011","indication_name":"Initial endocrine-based therapy for advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kisqali","generic_name":"LEE011","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase 4","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"3600","mechanism":"Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide."},{"drug_id":"lee011","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kisqali","generic_name":"LEE011","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase 4","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"3600","mechanism":"Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide."},{"drug_id":"lisdexamfetamine","indication_name":"Attention Deficit Hyperactivity Disorder (ADHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyvanse","generic_name":"LISDEXAMFETAMINE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Central Nervous System Stimulant","quality_score":80,"revenue":"3200","mechanism":"Vyvanse works by blocking the dopamine transporter, allowing more dopamine to be available in the brain."},{"drug_id":"etanercept","indication_name":"Nonradiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enbrel","generic_name":"etanercept","company_name":"Immunex","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":77,"revenue":"3100","mechanism":"Enbrel works by binding to tumor necrosis factor, a protein that promotes inflammation, thereby reducing inflammation and alleviating symptoms."},{"drug_id":"aripiprazole","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"ipilimumab","indication_name":"High grade squamous intraepithelial neoplasia of esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent esophageal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"trastuzumab-deruxtecan","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"ixekizumab","indication_name":"Non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taltz","generic_name":"ixekizumab","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Interleukin 17A (IL-17A) cytokine","drug_class":"Interleukin-17A antagonist","quality_score":82,"revenue":"2700","mechanism":"Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have received at least one prior therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who are not eligible for or have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have received at least one prior therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"mirabegron","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myrbetriq","generic_name":"MIRABEGRON","company_name":"Apgdi","drug_phase":"marketed","molecular_target":"Beta-3 adrenergic receptor","drug_class":"beta3-Adrenergic Agonist [EPC]","quality_score":71,"revenue":"1800","mechanism":"Myrbetriq works by activating the beta-3 adrenergic receptor in the bladder muscle, leading to relaxation and improved bladder control."},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"chembl-chembl48361","indication_name":"Treatment of DVT and PE in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Reduction of DVT and PE recurrence in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"tolvaptan","indication_name":"Polycystic kidney disease, adult type","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Samsca","generic_name":"TOLVAPTAN","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Vasopressin V2 receptor","drug_class":"Vasopressin V2 Receptor Antagonist [EPC]","quality_score":80,"revenue":"1200","mechanism":"Samsca works by blocking the action of vasopressin, a hormone that regulates water levels in the body."},{"drug_id":"cyclophosphamide","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"trastuzumab-emtansine","indication_name":"Adjuvant treatment of HER2-positive breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kadcyla","generic_name":"trastuzumab-emtansine","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"900","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent."},{"drug_id":"hyaluronidase","indication_name":"Subcutaneous Fluid Administration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wydase","generic_name":"HYALURONIDASE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"hyaluronic acid","drug_class":"Endoglycosidase","quality_score":10,"revenue":"900","mechanism":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids."},{"drug_id":"hyaluronidase","indication_name":"Subcutaneous clysis of patient for fluid administration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wydase","generic_name":"HYALURONIDASE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"hyaluronic acid","drug_class":"Endoglycosidase","quality_score":10,"revenue":"900","mechanism":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids."},{"drug_id":"ramucirumab","indication_name":"Adenocarcinoma of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"asciminib","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"dostarlimab","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jemperli","generic_name":"DOSTARLIMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"amivantamab","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rybrevant","generic_name":"AMIVANTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"EGFR, MET","drug_class":"","quality_score":59,"revenue":"800","mechanism":"Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells."},{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Prevention of migraine attacks in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"pf-07104091-monotherapy-dose-expansion-ovarian","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07104091 monotherapy dose expansion (ovarian)","generic_name":"pf-07104091-monotherapy-dose-expansion-ovarian","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[insert molecular target]","drug_class":"small molecule","quality_score":35,"revenue":"798","mechanism":""},{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"selpercatinib","indication_name":"Advanced RET fusion-positive thyroid cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"selpercatinib","indication_name":"Advanced RET fusion-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"belzutifan","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"galcanezumab","indication_name":"Treatment of episodic cluster headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emgality","generic_name":"GALCANEZUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"","quality_score":60,"revenue":"500","mechanism":"Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks."},{"drug_id":"dasatinib","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"dasatinib","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"exemestane","indication_name":"Advanced Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromasin","generic_name":"exemestane","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase Inhibitor [EPC]","quality_score":81,"revenue":"450","mechanism":"Aromasin works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens."},{"drug_id":"valsartan","indication_name":"Chronic heart failure in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults with a history of radiation therapy to the head.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of Prader-Willi syndrome in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of Turner syndrome in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"genotropin","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnitrope","generic_name":"Somatropin","company_name":"Serono","drug_phase":"marketed","molecular_target":"Dimeric GH receptors on cell membranes of target tissues","drug_class":"Recombinant human growth hormone","quality_score":10,"revenue":"446","mechanism":"Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1."},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of HIV-associated wasting in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"lonapegsomatropin","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skytrofa","generic_name":"LONAPEGSOMATROPIN","company_name":"Ascendis Pharma Encocrinology Div A/S","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":"446","mechanism":"Skytrofa works by mimicking the natural growth hormone to stimulate growth in individuals with growth hormone deficiency."},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of short bowel syndrome and failure to thrive in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"genotropin","indication_name":"Prader-Willi syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnitrope","generic_name":"Somatropin","company_name":"Serono","drug_phase":"marketed","molecular_target":"Dimeric GH receptors on cell membranes of target tissues","drug_class":"Recombinant human growth hormone","quality_score":10,"revenue":"446","mechanism":"Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1."},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of adult-onset growth hormone deficiency.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults with a history of pituitary surgery.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"nilotinib","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"olanzapine","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"erdafitinib","indication_name":"Locally advanced or metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Balversa","generic_name":"ERDAFITINIB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"300","mechanism":"Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread."},{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"abrocitinib-suspension-f1","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F1","generic_name":"abrocitinib-suspension-f1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":33,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f6","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F6","generic_name":"abrocitinib-suspension-f6","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"oxbryta","indication_name":"Treatment of sickle cell disease (SCD) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxbryta","generic_name":"Voxelotor","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Hemoglobin S (HbS)","drug_class":"Hemoglobin S polymerization inhibitor","quality_score":10,"revenue":"250","mechanism":"Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."},{"drug_id":"atogepant","indication_name":"Preventive treatment of episodic migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qulipta","generic_name":"ATOGEPANT","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist [EPC]","quality_score":66,"revenue":"201","mechanism":"Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain."},{"drug_id":"repotrectinib","indication_name":"Locally advanced or metastatic ROS1-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"talzenna","indication_name":"BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"tivdak","indication_name":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tisotumab Vedotin","generic_name":"tivdak","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":10,"revenue":"147","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"keppra","indication_name":"Myoclonic Epilepsy Adjunct Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"keppra","indication_name":"Tonic-Clonic Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab and in patients who are not eligible for pembrolizumab plus durvalumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum-containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum-containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab and in patients who are not eligible for nivolumab plus ipilimumab and in patients who are not eligible for pembrolizumab plus lenvatinib and in patients who are not eligible for avelumab plus alpelisib and in patients who are not eligible for pembrolizumab plus axicabtagene ciloleucel and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan and in patients who are not eligible for pembrolizumab plus atezolizumab and in patients who are not eligible for pembrolizumab plus nivolumab and in patients who are not eligible for pembrolizumab plus avelumab and in patients who are not eligible for pembrolizumab plus durvalumab and in patients who are not eligible for pembrolizumab plus sacituzumab govitecan plus cetrelimab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Triple-negative breast cancer with disease progression on or after chemotherapy in the neoadjuvant or adjuvant setting and/or in patients with measurable disease by RECIST v1.1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"doxycyclin","indication_name":"Periodontitis Adjunct Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tryptorelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tryptorelin","company_name":"Instituto Valenciano de Infertilidad, IVI VALENCIA","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Tetanus Adjunct Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"lyrica","indication_name":"Adjunctive therapy for partial-onset seizures in patients 1 month of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"aspartame","indication_name":"headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Addiclenz","generic_name":"ASPARTAME","company_name":"Deseret Biologicals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."},{"drug_id":"estradiol-valerate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol-valerate","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"5-fu","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"leuprorelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lupron","generic_name":"leuprorelin","company_name":"Accord Healthcare S.L.U.","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Leuprolide acetate, a long-acting GnRH analog, initially stimulates then suppresses pituitary gonadotropins, reducing gonadal steroid secretion."},{"drug_id":"citric-acid","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"CITRIC ACID","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Anti-coagulant","quality_score":50,"revenue":null,"mechanism":"Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones."},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"indigotindisulfonate","indication_name":"visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bludigo","generic_name":"INDIGOTINDISULFONATE","company_name":"Provepharm Sas","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Bludigo works by emitting a blue fluorescence when exposed to ultraviolet light, allowing for visualization of the ureters."},{"drug_id":"tolterodine","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Detrol","generic_name":"TOLTERODINE","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":63,"revenue":null,"mechanism":"Detrol works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle."},{"drug_id":"metaclopramide","indication_name":"Gastrointestinal Radiography Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metaclopramide","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"discontinued","molecular_target":"Aldehyde oxidase, Myeloperoxidase, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dapiprazole","indication_name":"Reverse Mydriasis from Ophthalmic Adrenergic or Anticholinergic Agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dapiprazole Hydrochloride","generic_name":"DAPIPRAZOLE","company_name":"Fera Pharms","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"diphenylpyraline","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hispril","generic_name":"DIPHENYLPYRALINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"diphenylpyraline","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"tripelennamine-citrate","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyribenzamin","generic_name":"TRIPELENNAMINE CITRATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"tripelennamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cetuximab","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"exjade","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Exjade","company_name":"DisperSol Technologies, LLC","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH), Lysine-specific demethylase 5A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mepyramine","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrilamine","generic_name":"mepyramine","company_name":"Impax Labs","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"norethisterone","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronor","generic_name":"norethisterone","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Progestin","quality_score":63,"revenue":null,"mechanism":"ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects."},{"drug_id":"lysine","indication_name":"Renal radiation exposure from Lutetium (177Lu) oxodotreotide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"L-Lysine","generic_name":"LYSINE","company_name":"Advanced Accelerator Applications","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"lysine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"gluconolactone","indication_name":"Urinary bladder stone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"GLUCONOLACTONE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"Glucosylceramidase","drug_class":"Calculi Dissolution Agent [EPC]","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"enhertu","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"botulinum-toxin-type-a","indication_name":"Neurogenic bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"botulinum-toxin-type-a","indication_name":"Overactive bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"andexanet-alfa","indication_name":"Direct acting anticoagulant adverse reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anxa","generic_name":"ANDEXANET ALFA","company_name":"Portola Pharamceuticals US","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Anxa works by binding to and neutralizing factor Xa inhibitors, reversing anticoagulation."},{"drug_id":"hydrocortisone-succinate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"colecalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"gemcitabin","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gemcitabin","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"ozone","indication_name":"head discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pollutox","generic_name":"OZONE","company_name":"Deseret Biologicals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Radiographic Contrast Agent [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"cosibelimab","indication_name":"locally advanced CSCC (laCSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unloxcyt","generic_name":"COSIBELIMAB","company_name":"Checkpoint Therapeutics Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells."},{"drug_id":"inbakicept","indication_name":"BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anktiva","generic_name":"INBAKICEPT","company_name":"Altor Bioscience, Llc, An Indirect Wholly-Owned Su","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Anktiva works by targeting a specific target to treat BCG-unresponsive nonmuscle invasive bladder cancer."},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"borofalan-10b","indication_name":"Neoplasm of head and neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Steboronine","generic_name":"borofalan (10B)","company_name":"Stella Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"butalbital","indication_name":"Tension-type headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butalbital, Aspirin And Caffeine","generic_name":"BUTALBITAL","company_name":"Actavis Labs Ut Inc","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"Barbiturate [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"undecanoate","indication_name":"Primary hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"undecanoate","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"calcitonin-salmon-synthetic","indication_name":"Hypercalcemia Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miacalcin","generic_name":"calcitonin (salmon synthetic)","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"calcitonin receptors","drug_class":"Calcitonin [EPC]","quality_score":55,"revenue":null,"mechanism":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract."},{"drug_id":"norethynodrel","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noretynodrel","generic_name":"NORETHYNODREL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"norethynodrel","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"phenylpropanolamine","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propadrine","generic_name":"PHENYLPROPANOLAMINE","company_name":"Alpharma Us Pharms","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Indirectly Acting Sympathomimetic Amines","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"brodalumab","indication_name":"Non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kyntheum","generic_name":"BRODALUMAB","company_name":"Valeant Luxembourg","drug_phase":"marketed","molecular_target":"Interleukin-17 receptor","drug_class":"Interleukin-17 Receptor A Antagonist [EPC]","quality_score":55,"revenue":null,"mechanism":"Kyntheum works by blocking the interleukin-17 receptor, a protein that plays a key role in inflammation."},{"drug_id":"edetic-acid","indication_name":"Accidental poisoning by lead and its compounds and fumes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcium Disodium Versenate","generic_name":"EDETIC ACID","company_name":"Medicis","drug_phase":"marketed","molecular_target":"Amyloid beta A4 protein","drug_class":"Anti-coagulant","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"antazoline","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenazoline","generic_name":"ANTAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"antazoline","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"carbetocin","indication_name":"Prader-Willi syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pabal","generic_name":"CARBETOCIN","company_name":"Ferring Pharmaceuticals Ltd","drug_phase":"marketed","molecular_target":"Oxytocin receptor","drug_class":"carbetocin","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"dimercaprol","indication_name":"Accidental poisoning by lead and its compounds and fumes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bal","generic_name":"DIMERCAPROL","company_name":"Provepharm Sas","drug_phase":"marketed","molecular_target":"","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"apap","indication_name":"headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated","generic_name":"APAP","company_name":"HF Acquisition Co LLC, DBA HealthFirst","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"pentetate-calcium-trisodium","indication_name":"Exposure to Americium Radiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pentetate Calcium Trisodium","generic_name":"PENTETATE CALCIUM TRISODIUM","company_name":"Hameln","drug_phase":"marketed","molecular_target":"","drug_class":"pentetate calcium trisodium","quality_score":10,"revenue":null,"mechanism":"Pentetate Calcium Trisodium works by binding to radioactive ions, such as Americium, Curium, and Plutonium, to facilitate their excretion from the body."},{"drug_id":"pentetate-calcium-trisodium","indication_name":"Exposure to Curium Radiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pentetate Calcium Trisodium","generic_name":"PENTETATE CALCIUM TRISODIUM","company_name":"Hameln","drug_phase":"marketed","molecular_target":"","drug_class":"pentetate calcium trisodium","quality_score":10,"revenue":null,"mechanism":"Pentetate Calcium Trisodium works by binding to radioactive ions, such as Americium, Curium, and Plutonium, to facilitate their excretion from the body."},{"drug_id":"pentetate-calcium-trisodium","indication_name":"Exposure to Plutonium Radiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pentetate Calcium Trisodium","generic_name":"PENTETATE CALCIUM TRISODIUM","company_name":"Hameln","drug_phase":"marketed","molecular_target":"","drug_class":"pentetate calcium trisodium","quality_score":10,"revenue":null,"mechanism":"Pentetate Calcium Trisodium works by binding to radioactive ions, such as Americium, Curium, and Plutonium, to facilitate their excretion from the body."},{"drug_id":"midazolam-hydrochloride","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"Midazolam Hydrochloride","company_name":"Takeda Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-5/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":58,"revenue":null,"mechanism":""},{"drug_id":"midazolam-hydrochloride","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"Midazolam Hydrochloride","company_name":"Takeda Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-5/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":58,"revenue":null,"mechanism":""},{"drug_id":"estradiol","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"quetiapine","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"cholecalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"deferoxamine","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Desferal","generic_name":"DEFEROXAMINE","company_name":"Mitem Pharma","drug_phase":"marketed","molecular_target":"Deoxyhypusine hydroxylase","drug_class":"Iron Chelator","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"methocarbamol","indication_name":"Tetanus Adjunct Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Robaxin","generic_name":"METHOCARBAMOL","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Muscle Relaxant [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"diclofenac","indication_name":"Adhesive capsulitis of shoulder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voltaren","generic_name":"DICLOFENAC","company_name":"Hisamitsu Pharmaceutical Co., Inc","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bromocriptine","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"gemcitabine-hydrochloride","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"Gemcitabine Hydrochloride","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase; DNA incorporation","drug_class":"Nucleoside metabolic inhibitor","quality_score":69,"revenue":null,"mechanism":"Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression."},{"drug_id":"formoterol","indication_name":"Adjunct Therapy to Achieve Long-term Asthma Control","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"bleomycin","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"neostigmine","indication_name":"Reversal of neuromuscular blockade","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bloxiverz","generic_name":"NEOSTIGMINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Bloxiverz works by blocking the enzyme acetylcholinesterase, allowing more acetylcholine to be available in the nervous system."},{"drug_id":"glucagon","indication_name":"Gastrointestinal Radiography Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucagen","generic_name":"GLUCAGON","company_name":"Xeris","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Antihypoglycemic Agent","quality_score":10,"revenue":null,"mechanism":"Glucagen works by stimulating the release of glucose from stored energy sources in the body."},{"drug_id":"midazolam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"midazolam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2","drug_class":"Benzodiazepine (short-acting)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"midazolam","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"midazolam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2","drug_class":"Benzodiazepine (short-acting)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"testosterone","indication_name":"Chemotherapy-Induced Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cortisone","indication_name":"headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immune Support","generic_name":"CORTISONE","company_name":"Merck","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"goserelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"goserelin","company_name":"Tersera","drug_phase":"marketed","molecular_target":"pituitary gonadotropin secretion","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors."},{"drug_id":"goserelin","indication_name":"Endometrial Ablation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"goserelin","company_name":"Tersera","drug_phase":"marketed","molecular_target":"pituitary gonadotropin secretion","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors."},{"drug_id":"goserelin-acetate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"GOSERELIN ACETATE","company_name":"Tersera","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"Zoladex works by mimicking the body's natural hormone to reduce testosterone production."},{"drug_id":"goserelin-acetate","indication_name":"Endometrial Ablation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"GOSERELIN ACETATE","company_name":"Tersera","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"Zoladex works by mimicking the body's natural hormone to reduce testosterone production."},{"drug_id":"ergocalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"mobocertinib","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exkivity","generic_name":"MOBOCERTINIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-4","drug_class":"Kinase Inhibitor","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"toripalimab","indication_name":"metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loqtorzi","generic_name":"TORIPALIMAB","company_name":"Coherus Biosciences Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"cortisone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"adenosine","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenocard","generic_name":"ADENOSINE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Adenosine Receptor Agonist [EPC]","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"elacestrant","indication_name":"ESR1-mutated advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"elacestrant","indication_name":"Estrogen receptor positive advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"elacestrant","indication_name":"HER2-negative advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orserdu","generic_name":"ELACESTRANT","company_name":"Stemline Therap","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow."},{"drug_id":"larotrectinib","indication_name":"NTRK fusion gene-positive advanced or recurrent solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitrakvi","generic_name":"LAROTRECTINIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"mepivacaine","indication_name":"Administration of Local Anesthetic Nerve Block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carbocaine","generic_name":"MEPIVACAINE","company_name":"Eastman Kodak","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha","drug_class":"Amide Local Anesthetic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"mepivacaine","indication_name":"Administration of Regional Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carbocaine","generic_name":"MEPIVACAINE","company_name":"Eastman Kodak","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha","drug_class":"Amide Local Anesthetic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"elapegademase","indication_name":"Adenosine deaminase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."},{"drug_id":"elapegademase","indication_name":"SCID due to absent adenosine deaminase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."},{"drug_id":"nsaid","indication_name":"headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Excedrin Extra Strength Pain Reliever","generic_name":"NSAID","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Cyclooxygenase","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metoclopramide","indication_name":"Gastrointestinal Radiography Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reglan","generic_name":"METOCLOPRAMIDE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Dopamine-2 Receptor Antagonist","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"depo-testosterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trospium","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sanctura","generic_name":"TROSPIUM","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":63,"revenue":null,"mechanism":"Sanctura works by blocking the action of a chemical called acetylcholine at the M3 receptor in the bladder muscle, reducing muscle contractions and urgency."},{"drug_id":"metoclopramide-hydrochloride","indication_name":"Gastrointestinal Radiography Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reglan","generic_name":"Metoclopramide Hydrochloride","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Acetylcholine receptor sensitization; dopamine antagonism (implied)","drug_class":"Prokinetic agent","quality_score":10,"revenue":null,"mechanism":"Metoclopramide stimulates upper GI tract motility by sensitizing tissues to acetylcholine action."},{"drug_id":"cisplatin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"leuprolide","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lupron","generic_name":"leuprolide","company_name":"Accord Healthcare S.L.U.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Lupron works by binding to and activating the gonadotropin-releasing hormone receptor, which ultimately leads to a decrease in the production of sex hormones."},{"drug_id":"iodamide","indication_name":"Computed tomography of entire head","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ametriodic Acid","generic_name":"IODAMIDE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"iodamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"iodamide","indication_name":"Digestive System Radiography","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ametriodic Acid","generic_name":"IODAMIDE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"iodamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"iodamide","indication_name":"Radiographic imaging procedure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ametriodic Acid","generic_name":"IODAMIDE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"iodamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"iodamide","indication_name":"Retrograde Cystourethrography","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ametriodic Acid","generic_name":"IODAMIDE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"iodamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"iodamide","indication_name":"Retrograde pyelogram","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ametriodic Acid","generic_name":"IODAMIDE","company_name":"Bracco","drug_phase":"marketed","molecular_target":"","drug_class":"iodamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"estrone-sulphate","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ogen .625","generic_name":"estrone sulphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Steryl-sulfatase","drug_class":"estropipate","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"dmae","indication_name":"headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dmae 1549","generic_name":"DMAE","company_name":"Professional Complementary Health Formulas","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"fludarabine-phosphate","indication_name":"Low-grade B cell non-Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"glycopyrronium-bromide","indication_name":"Vagal Reflex Bradycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cuvposa","generic_name":"GLYCOPYRRONIUM BROMIDE","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":62,"revenue":null,"mechanism":"Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body."},{"drug_id":"caffeine","indication_name":"Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Tension-type headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Vascular headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ferric-hexacyanoferrateii","indication_name":"Radioactive Cesium Decontamination","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RADIOGARDASE (PRUSSIAN BLUE)","generic_name":"FERRIC HEXACYANOFERRATE(II)","company_name":"HEYL CHEMISCH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hematoporphyrin","indication_name":"Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Photodyn","generic_name":"Hematoporphyrin","company_name":"Hepatopancreatobiliary Surgery Institute of Gansu Province","drug_phase":"phase_1","molecular_target":"","drug_class":"hematoporphyrin","quality_score":null,"revenue":null,"mechanism":"Photodyn works by being activated by light, which then kills cancer cells through a process called photodynamic therapy."},{"drug_id":"hematoporphyrin","indication_name":"High Grade Dysplasia associated with Barrett's Esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Photodyn","generic_name":"Hematoporphyrin","company_name":"Hepatopancreatobiliary Surgery Institute of Gansu Province","drug_phase":"phase_1","molecular_target":"","drug_class":"hematoporphyrin","quality_score":null,"revenue":null,"mechanism":"Photodyn works by being activated by light, which then kills cancer cells through a process called photodynamic therapy."},{"drug_id":"bupropion-sr-150mg-bid","indication_name":"Prevention of Seasonal Affective Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupropion SR 150mg bid","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Atypical antidepressant, Norepinephrine-dopamine reuptake inhibitor (NDRI)","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Tuberculosis Meningitis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"potassium-iodide","indication_name":"Thyroid Gland Radiation Protection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Iodide","generic_name":"POTASSIUM IODIDE","company_name":"Roxane","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 4","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fludrocortisone-acetate","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"FLUDROCORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"fludrocortisone","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"fludrocortisone-acetate","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"FLUDROCORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"fludrocortisone","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"erdosteine","indication_name":"Accidental poisoning by lead and its compounds and fumes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dithiosteine","generic_name":"ERDOSTEINE","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"erdosteine","quality_score":27,"revenue":null,"mechanism":"Erdosteine works by binding to heavy metals and facilitating their excretion from the body."},{"drug_id":"mitomycin","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Adjunct to incisional glaucoma surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"aromasin","indication_name":"Advanced Breast Cancer Progression Post-Antiestrogen Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aromasin","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Androgen receptor, Aromatase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"vesicare","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vesicare","company_name":"University of California, Irvine","drug_phase":"discontinued","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"lutetium-177lu-chloride","indication_name":"Radiolabelling of carrier molecules","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumark","generic_name":"lutetium (177Lu) chloride","company_name":"I.D.B. Radiopharmacy B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"guaifenesin","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mucinex","generic_name":"guaifenesin","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Vagal gastric reflex → increased respiratory secretions","drug_class":"Expectorant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"guaifenesin","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mucinex","generic_name":"guaifenesin","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Vagal gastric reflex → increased respiratory secretions","drug_class":"Expectorant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"calcium-chloride","indication_name":"Skin Grafting Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plegisol In Plastic Container","generic_name":"CALCIUM CHLORIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"calcium chloride","quality_score":50,"revenue":null,"mechanism":"Calcium chloride works by replenishing calcium levels in the body, which is essential for maintaining proper muscle and nerve function."},{"drug_id":"calcium-chloride","indication_name":"Surgical Hemostasis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plegisol In Plastic Container","generic_name":"CALCIUM CHLORIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"calcium chloride","quality_score":50,"revenue":null,"mechanism":"Calcium chloride works by replenishing calcium levels in the body, which is essential for maintaining proper muscle and nerve function."},{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type V hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Treatment of adult patients with triglyceride elevations between 1,000-2,000 mg/dL and history of pancreatitis or recurrent abdominal pain typical of pancreatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"etrasimod","indication_name":"Induction of remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Induction of clinical remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"menest","indication_name":"Female hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"menest","indication_name":"Prostatic carcinoma - palliative therapy of advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"synarel","indication_name":"Treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"synarel","indication_name":"Exclusion of other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"fabrazyme-agalsidase-beta","indication_name":"Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fabrazyme (agalsidase beta)","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)","drug_class":"Enzyme replacement therapy (ERT); recombinant enzyme","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"MRI of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Reduction of thrombotic cardiovascular events in patients with atherosclerotic disease, including those with a recent ischemic stroke or peripheral artery disease (PAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"adalimumab","indication_name":"Hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"aldactone","indication_name":"Hypertension as add-on therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"aldactone","indication_name":"Edema in nephrotic syndrome with inadequate response to other treatments","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"tetracosactide","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortrosyn","generic_name":"tetracosactide","company_name":"Amphastar Pharms Inc","drug_phase":"marketed","molecular_target":"Melanocortin receptor 4","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tetracosactide","indication_name":"Diagnostic Test for Secondary Adrenocortical Insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortrosyn","generic_name":"tetracosactide","company_name":"Amphastar Pharms Inc","drug_phase":"marketed","molecular_target":"Melanocortin receptor 4","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"paroxetine","indication_name":"Social Anxiety Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paroxetine","generic_name":"paroxetine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":73,"revenue":null,"mechanism":"Inhibits neuronal reuptake of serotonin in the central nervous system, presumed mechanism for treating psychiatric disorders."},{"drug_id":"paroxetine","indication_name":"Generalized Anxiety Disorder (GAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paroxetine","generic_name":"paroxetine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":73,"revenue":null,"mechanism":"Inhibits neuronal reuptake of serotonin in the central nervous system, presumed mechanism for treating psychiatric disorders."},{"drug_id":"duratocin","indication_name":"Prader-Willi syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Duratocin","company_name":"Dongyu Wang","drug_phase":"phase_1","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Non-Radiographic Axial Spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Adjuvant chemotherapy for women with axillary lymph node involvement following resection of primary breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic transitional cell bladder carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"fragmin","indication_name":"Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"levophed","indication_name":"Severe, acute hypotension in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levophed","generic_name":"Norepinephrine Bitartrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-adrenergic and beta-adrenergic receptors","drug_class":"Catecholamine, sympathomimetic amine","quality_score":10,"revenue":null,"mechanism":"Peripheral vasoconstrictor via alpha-adrenergic action and cardiac inotropic stimulator with coronary vasodilation via beta-adrenergic action."},{"drug_id":"levophed","indication_name":"Acute hypotensive states in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levophed","generic_name":"Norepinephrine Bitartrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-adrenergic and beta-adrenergic receptors","drug_class":"Catecholamine, sympathomimetic amine","quality_score":10,"revenue":null,"mechanism":"Peripheral vasoconstrictor via alpha-adrenergic action and cardiac inotropic stimulator with coronary vasodilation via beta-adrenergic action."},{"drug_id":"levophed","indication_name":"Blood pressure restoration in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levophed","generic_name":"Norepinephrine Bitartrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-adrenergic and beta-adrenergic receptors","drug_class":"Catecholamine, sympathomimetic amine","quality_score":10,"revenue":null,"mechanism":"Peripheral vasoconstrictor via alpha-adrenergic action and cardiac inotropic stimulator with coronary vasodilation via beta-adrenergic action."},{"drug_id":"gbt021601","indication_name":"Treatment of adult patients with severe hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gbt021601","generic_name":"gbt021601","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with other conditions that compromise the immune system.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose and a twelfth dose administered at least 2 months after the eleventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 50 years of age and older.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with functional or anatomic asplenia.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with HIV infection.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic kidney disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic liver disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic lung disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with diabetes.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with alcohol use disorder.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Hospitalized Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Bacterial Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Community-Acquired Pneumonia in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Sinus Bradycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with a tumor harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of postherpetic neuralgia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of neuropathic pain associated with diabetic peripheral neuropathy in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of fibromyalgia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of chronic pain associated with adult patients with multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of post-traumatic stress disorder (PTSD) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of treatment-resistant depression in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of major depressive disorder in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of generalized anxiety disorder in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of insomnia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tofacitinib-xeljanz","indication_name":"Atopic Dermatitis (AD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib (Xeljanz)","generic_name":"tofacitinib-xeljanz","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK3","drug_class":"Janus Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bupropion-immediate-release-ir","indication_name":"Seasonal Affective Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bupropion immediate release (IR)","generic_name":"bupropion-immediate-release-ir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dopamine transporter, Norepinephrine transporter","drug_class":"Norepinephrine-dopamine reuptake inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Tetanus, diphtheria, and pertussis toxoids adsorbed (Tdap) booster dose in individuals 11 through 64 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adolescents 11 through 12 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adolescents 13 through 18 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adults 19 through 26 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for adults 19 through 26 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of adults 27 years of age and older who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for adults 27 years of age and older who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"leucovorin","indication_name":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wellcovorin","generic_name":"leucovorin","company_name":"Pfizer Japan Inc","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Folate Analog","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"leucovorin","indication_name":"Sulfadiazine Toxicity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wellcovorin","generic_name":"leucovorin","company_name":"Pfizer Japan Inc","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Folate Analog","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"nirmatrelvir-ritonavir","indication_name":"Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"nirmatrelvir-ritonavir","generic_name":"nirmatrelvir-ritonavir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 protease enzyme","drug_class":"Protease inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"fludrocortisone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"fludrocortisone","company_name":"Generic","drug_phase":"marketed","molecular_target":"Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Mineralocorticoid","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"fludrocortisone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"fludrocortisone","company_name":"Generic","drug_phase":"marketed","molecular_target":"Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Mineralocorticoid","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"gleevec","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the thyroid gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the heart","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the small intestine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"rimegepant-for-acute-migraine-treatment","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant for acute migraine treatment","generic_name":"rimegepant-for-acute-migraine-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":54,"revenue":null,"mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine."},{"drug_id":"folfiri","indication_name":"Adjuvant treatment of colon cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the peritoneum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the anus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the small intestine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the heart","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the thyroid gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the uterus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the testes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the uterus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the testes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the uterus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the testes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the uterus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the testes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the uterus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the testes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the uterus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the testes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the adrenal gland","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options would be otherwise inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"pembrolizuma","indication_name":"Advanced or recurrent cervical cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"lorazepam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lorazepam","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pethidine","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pethidine","company_name":"","drug_phase":"unknown","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"calciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"adagen","indication_name":"Adenosine deaminase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adagen","company_name":"Leadiant Biosciences, Inc.","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"lacosamide","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vimpat","generic_name":"lacosamide","company_name":"UCB","drug_phase":"marketed","molecular_target":"Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"diprivan","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diprivan","company_name":"St. Antonius Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9, Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ergot","indication_name":"Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ergot","company_name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ergot","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ergot","company_name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ergot","indication_name":"Vascular headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ergot","company_name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"dostarlimab-gxly","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"codeine","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Codeine","generic_name":"codeine phosphate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"Opioid analgesic, Antitussive","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"codeine","indication_name":"Tension-type headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Codeine","generic_name":"codeine phosphate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"Opioid analgesic, Antitussive","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"taxotere","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Chemotherapy-Induced Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"High grade squamous intraepithelial neoplasia of esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent esophageal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"glycopyrrolate","indication_name":"Vagal Reflex Bradycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glycopyrrolate","company_name":"Yonsei University","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"omnitrope","indication_name":"Prader-Willi syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omnitrope","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"omnitrope","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omnitrope","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"clorazepate","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tranxene","generic_name":"clorazepate","company_name":"Ajenat Pharms","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"diazepam-2mg-encapsulated-tab","indication_name":"Adjunctive treatment in convulsive disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diazepam 2Mg encapsulated Tab","company_name":"The University of Hong Kong","drug_phase":"marketed","molecular_target":"GABA-A receptor (allosteric modulator)","drug_class":"Benzodiazepine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"palazestrant","indication_name":"Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palazestrant","generic_name":"palazestrant","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor antagonist and degrader","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75mg-orally-disintegrating-tablets-odt","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","generic_name":"rimegepant-75mg-orally-disintegrating-tablets-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":51,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"adalimumab-adbm","indication_name":"Hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"taltz","indication_name":"Non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taltz","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"somapacitan-beco","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"alendronate","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alendronate","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"amivantamab-vmjw","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYBREVANT","generic_name":"AMIVANTAMAB-VMJW","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"relatlimab-rmbw","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Prevention of migraine attacks in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"pantoprazole","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"velsipity","indication_name":"Induction of remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Induction of clinical remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"oxymesterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"oxymesterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"oxymesterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"ephedrine","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akovaz","generic_name":"EPHEDRINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"Norepinephrine Releasing Agent","quality_score":52,"revenue":null,"mechanism":"Akovaz works by releasing norepinephrine, a natural chemical in the body that helps to relieve symptoms of respiratory and allergic conditions."},{"drug_id":"ephedrine","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akovaz","generic_name":"EPHEDRINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"Norepinephrine Releasing Agent","quality_score":52,"revenue":null,"mechanism":"Akovaz works by releasing norepinephrine, a natural chemical in the body that helps to relieve symptoms of respiratory and allergic conditions."},{"drug_id":"estrone","indication_name":"Prevention of Radiation-Induced Nausea and Vomiting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estron","generic_name":"ESTRONE","company_name":"Watson Labs","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"estrone","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aceclofenac","indication_name":"Adhesive capsulitis of shoulder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hifenac","generic_name":"ACECLOFENAC","company_name":"","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"aceclofenac","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"butacaine","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butyn","generic_name":"BUTACAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"butacaine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"butacaine","indication_name":"Neurogenic bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butyn","generic_name":"BUTACAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"butacaine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"crinecerfont","indication_name":"classic congenital adrenal hyperplasia (CAH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crenessity","generic_name":"CRINECERFONT","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"","drug_class":"Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones."},{"drug_id":"estring","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estring","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"fluoxymesterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluoxymesterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluoxymesterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"protonix-iv","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"ceftriaxon","indication_name":"Adult Gonococcal Conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chantix","indication_name":"Treatment of adult smokers to help them stop smoking","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chantix","generic_name":"Varenicline Tartrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α4β2 neuronal nicotinic acetylcholine receptors","drug_class":"Nicotinic receptor partial agonist","quality_score":77,"revenue":null,"mechanism":"Varenicline binds α4β2 neuronal nicotinic acetylcholine receptors as partial agonist, blocking nicotine binding and dopamine reward."},{"drug_id":"chantix","indication_name":"Treatment of adult smokers with a history of serious psychiatric illness to help them stop smoking","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chantix","generic_name":"Varenicline Tartrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α4β2 neuronal nicotinic acetylcholine receptors","drug_class":"Nicotinic receptor partial agonist","quality_score":77,"revenue":null,"mechanism":"Varenicline binds α4β2 neuronal nicotinic acetylcholine receptors as partial agonist, blocking nicotine binding and dopamine reward."},{"drug_id":"levoxyl","indication_name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."},{"drug_id":"levoxyl","indication_name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."},{"drug_id":"levoxyl","indication_name":"Hypothyroidism in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."},{"drug_id":"loncastuximab","indication_name":"DLBCL arising from low-grade lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynlonta","generic_name":"LONCASTUXIMAB","company_name":"ADC Therapeutics SA","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction."},{"drug_id":"loncastuximab","indication_name":"high-grade B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynlonta","generic_name":"LONCASTUXIMAB","company_name":"ADC Therapeutics SA","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction."},{"drug_id":"alendronic-acid","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fosamax","generic_name":"ALENDRONIC ACID","company_name":"Merck And Co Inc","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Vitamin D [EPC]","quality_score":63,"revenue":null,"mechanism":"Fosamax works by inhibiting bone resorption, allowing bone density to increase."},{"drug_id":"busilvex","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexpanthenol","indication_name":"Toxicodendron radicans","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"DEXPANTHENOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"dexpanthenol","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Vitrectomy Adjunct to Enhance Visualization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pegademase","indication_name":"Adenosine deaminase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pegademase","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"levetiracetam","indication_name":"Myoclonic Epilepsy Adjunct Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"levetiracetam","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"levetiracetam","indication_name":"Tonic-Clonic Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"pethidin","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pethidin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"docetaxol","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"gabapentin","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"gabapentin","company_name":"Generic (originally Parke-Davis/Pfizer)","drug_phase":"marketed","molecular_target":"Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor","drug_class":"Gabapentinoid (anticonvulsant/neuropathic pain agent)","quality_score":10,"revenue":null,"mechanism":"Binds the alpha-2-delta subunit of voltage-gated calcium channels, modulating neurotransmitter release to treat neuropathic pain and seizures."},{"drug_id":"regadenoson","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Regadenoson","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"A2A adenosine receptor","drug_class":"Adenosine receptor agonist","quality_score":61,"revenue":null,"mechanism":"Regadenoson is a low affinity A2A adenosine receptor agonist that produces coronary vasodilation and increases coronary blood flow."},{"drug_id":"methapyrilene","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thenylene","generic_name":"METHAPYRILENE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gran","indication_name":"Prevention of Radiation-Induced Nausea and Vomiting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GRAN®","company_name":"EVIVE Biotechnology","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 2","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"lithium","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"persantin","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Persantin","company_name":"Boehringer Ingelheim","drug_phase":"phase_1","molecular_target":"Equilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epinephrine","indication_name":"Administration of Local Anesthetic Nerve Block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"phenobarbitone","indication_name":"Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenobarbitone","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenobarbitone","indication_name":"Vascular headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ibuprofen","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advil","generic_name":"ibuprofen","company_name":"Generic (originally Boots Group)","drug_phase":"marketed","molecular_target":"Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":40,"revenue":null,"mechanism":"Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation."},{"drug_id":"ibuprofen","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advil","generic_name":"ibuprofen","company_name":"Generic (originally Boots Group)","drug_phase":"marketed","molecular_target":"Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":40,"revenue":null,"mechanism":"Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation."},{"drug_id":"hydroxyurea","indication_name":"Locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"testosterone-cypionate-200mg-3ml","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosterone cypionate (200mg/3ml)","company_name":"Leticia Maria Defendi Barboza Marson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgenic steroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"acetylsalicylic-acid","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"acetylsalicylic-acid","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"articaine","indication_name":"Administration of Local Anesthetic Nerve Block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Septocaine","generic_name":"ARTICAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"Amide Local Anesthetic","quality_score":65,"revenue":null,"mechanism":"Articaine HCl blocks nerve impulses by increasing the threshold for electrical excitation, slowing nerve impulse propagation, and reducing the rate of rise of the action potential."},{"drug_id":"dextroamphetamine","indication_name":"Attention Deficit Hyperactivity Disorder (ADHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROAMPHETAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Central nervous system stimulant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mer","indication_name":"Temporary relief of headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mer Detox 6019","generic_name":"mer","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fytic-acid","indication_name":"Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phyliance","generic_name":"fytic acid","company_name":"PDRadiopharma Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"cosyntropin","indication_name":"Screening for adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COSYNTROPIN","company_name":"","drug_phase":"marketed","molecular_target":"MC2 receptor","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imidafenacin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uritos","generic_name":"IMIDAFENACIN","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"aciphex","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"propranolol","indication_name":"Pheochromocytoma Adjunct Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pseudoephedrine","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed","generic_name":"pseudoephedrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"Nasal decongestant (sympathomimetic)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pseudoephedrine","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed","generic_name":"pseudoephedrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"Nasal decongestant (sympathomimetic)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-bhv3000","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-bhv3000","indication_name":"Prevention of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"exenatide","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Byetta","generic_name":"EXENATIDE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Byetta works by mimicking the action of a natural hormone in the body to regulate blood sugar levels."},{"drug_id":"lithium-carbonate","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"toviaz","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toviaz","generic_name":"Fesoterodine Fumarate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"fesoterodine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-25-mg","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-25-mg","indication_name":"Prevention of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Cluster Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"gemcitabine","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"gemcitabine","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"DNA polymerase (alpha/delta/epsilon)","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process."},{"drug_id":"dihydroergotamine","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migranal","generic_name":"DIHYDROERGOTAMINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Ergotamine Derivative","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dihydroergotamine","indication_name":"Vascular headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migranal","generic_name":"DIHYDROERGOTAMINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Ergotamine Derivative","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"irinotecan","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I","drug_class":"Topoisomerase Inhibitor","quality_score":76,"revenue":null,"mechanism":"Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks."},{"drug_id":"tranexamic-acid","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyklokapron","generic_name":"TRANEXAMIC ACID","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"Antifibrinolytic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis."},{"drug_id":"histrelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantas","generic_name":"HISTRELIN","company_name":"","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Vantas works by binding to the gonadotropin-releasing hormone receptor, mimicking the natural hormone and reducing the production of sex hormones."},{"drug_id":"paracetamol","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"paracetamol","indication_name":"Pain Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"paracetamol","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"paracetamol","indication_name":"Tension-type headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"demerol","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meperidine Hydrochloride Preservative Free","generic_name":"Meperidine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":72,"revenue":null,"mechanism":"Meperidine Hydrochloride Preservative Free works by binding to opioid receptors in the brain, altering the perception of and response to pain."},{"drug_id":"fluorouracil","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"colesevelam","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welchol","generic_name":"COLESEVELAM","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":10,"revenue":null,"mechanism":"Welchol works by binding to bile acids in the gut, reducing their reabsorption and increasing their excretion, which in turn lowers cholesterol levels and improves blood sugar control."},{"drug_id":"cimetidine","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagamet","generic_name":"CIMETIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"vorasidenib","indication_name":"Grade 2 astrocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voranigo","generic_name":"VORASIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1."},{"drug_id":"vorasidenib","indication_name":"Grade 2 oligodendroglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voranigo","generic_name":"VORASIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1."},{"drug_id":"estradiol-cypionate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"estradiol-cypionate","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"asciminib-hydrochloride","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB HYDROCHLORIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ABL1 kinase of BCR::ABL1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Asciminib binds to the ABL myristoyl pocket, inhibiting ABL1 kinase activity of BCR::ABL1, including mutant forms."},{"drug_id":"fesoterodine","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toviaz","generic_name":"FESOTERODINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"fesoterodine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"edrophonium","indication_name":"Reversal of neuromuscular blockade","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tensilon","generic_name":"EDROPHONIUM","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"torisel","indication_name":"advanced renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"Temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"temsirolimus","quality_score":10,"revenue":null,"mechanism":"Temsirolimus is an inhibitor of mTOR, a protein that controls cell division."},{"drug_id":"dexmedetomidine-hydrochloride","indication_name":"Sedation of mechanically ventilated adult patients in an intensive care unit or coronary care unit.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexmedetomidine Hydrochloride","generic_name":"dexmedetomidine-hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"dexmedetomidine","quality_score":80,"revenue":null,"mechanism":"Dexmedetomidine Hydrochloride is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties."},{"drug_id":"dexmedetomidine-hydrochloride","indication_name":"Sedation of intubated and mechanically ventilated adult patients in an intensive care unit or coronary care unit.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexmedetomidine Hydrochloride","generic_name":"dexmedetomidine-hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"dexmedetomidine","quality_score":80,"revenue":null,"mechanism":"Dexmedetomidine Hydrochloride is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties."},{"drug_id":"arthrotec","indication_name":"Adhesive capsulitis of shoulder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arthrotec","generic_name":"Diclofenac Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acid-sensing ion channel 3","drug_class":"diclofenac","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"repaglinide","indication_name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prandin","generic_name":"repaglinide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family C member 8","drug_class":"Glinide [EPC]","quality_score":10,"revenue":null,"mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory advanced follicular lymphoma (FL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"leuprolide-acetate","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leuprolide Acetate","generic_name":"leuprolide-acetate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"leuprorelin","quality_score":10,"revenue":null,"mechanism":"Leuprolide acetate is a manufactured version of a hormone that regulates growth and development, used to treat hormone-related conditions."},{"drug_id":"bcg","indication_name":"Treatment of bladder cancer (superficial)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of high-grade non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of high-risk non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-grade tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"recombinant-antithrombin-rhat","indication_name":"Subcutaneous Fluid Administration for Achieving Hydration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Recombinant antithrombin (rhAT)","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Hyaluronic acid and connective tissue polysaccharides","drug_class":"Dispersion agent; enzyme","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"recombinant-antithrombin-rhat","indication_name":"Improving Resorption of Radiopaque Agents in Subcutaneous Urography","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Recombinant antithrombin (rhAT)","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Hyaluronic acid and connective tissue polysaccharides","drug_class":"Dispersion agent; enzyme","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"licensed-influenza-vaccine-2","indication_name":"Influenza prevention for adults and children 6 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Licensed Influenza Vaccine 2","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"benzhydrocodone","indication_name":"Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"benzhydrocodone","indication_name":"Use in patients for whom alternative treatment options have not provided adequate analgesia or are not expected to provide adequate analgesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"fospropofol","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lusedra","generic_name":"FOSPROPOFOL","company_name":"","drug_phase":"marketed","molecular_target":"GABA-A receptor","drug_class":"fospropofol","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, and/or prior radiotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, and/or prior chemotherapy with a platinum agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, and/or prior chemotherapy with a microtubule inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, and/or prior chemotherapy with a PARP inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, and/or prior chemotherapy with a mTOR inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, and/or prior chemotherapy with a HER2-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, and/or prior chemotherapy with a PIK3CA-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, and/or prior chemotherapy with a hormone receptor antagonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, and/or prior chemotherapy with a hormone receptor agonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, and/or prior chemotherapy with a selective estrogen receptor degrader","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, and/or prior chemotherapy with a selective estrogen receptor modulator","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, and/or prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor and/or a PIK3CA inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"solifenacin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vesicare","generic_name":"SOLIFENACIN","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":80,"revenue":null,"mechanism":"Vesicare works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle, reducing muscle contractions and urgency."},{"drug_id":"imatinib","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"golimumab","indication_name":"Nonradiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Simponi","generic_name":"GOLIMUMAB","company_name":"Centocor Ortho Biotech Inc","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":60,"revenue":null,"mechanism":"Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation."},{"drug_id":"hz-su-vaccine","indication_name":"Prevention of herpes zoster (shingles) in adults 50 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"HZ/su VACCINE","generic_name":"hz-su-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Prevention of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of COVID-19","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-hydrochloride","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"Irinotecan Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":79,"revenue":null,"mechanism":"Camptosar works by blocking the enzyme topoisomerase I, which is necessary for DNA replication, thereby preventing cancer cells from dividing and growing."},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Administration of Local Anesthetic Nerve Block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"deferasirox","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exjade","generic_name":"DEFERASIROX","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH)","drug_class":"Iron Chelator [EPC]","quality_score":10,"revenue":null,"mechanism":"Exjade works by binding to iron in the body and removing it through the urine."},{"drug_id":"erlotinib","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tarceva","generic_name":"erlotinib","company_name":"Osi Pharms","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tisagenlecleucel","indication_name":"high grade B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"porfimer","indication_name":"Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Photofrin","generic_name":"porfimer","company_name":"Concordia Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Photoactivated Radical Generator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"porfimer","indication_name":"High Grade Dysplasia associated with Barrett's Esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Photofrin","generic_name":"porfimer","company_name":"Concordia Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Photoactivated Radical Generator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"arginine","indication_name":"Renal radiation exposure from Lutetium (177Lu) oxodotreotide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"R-Gene 10","generic_name":"ARGININE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, inducible","drug_class":"arginine hydrochloride","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"capecitabine","indication_name":"Adjuvant treatment of Stage III colon cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"methylprednisolone-acetate","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"methylprednisolone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"corifollitropin-alfa","indication_name":"Adolescent males with hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Org 36286","generic_name":"CORIFOLLITROPIN ALFA","company_name":"Merck Sharp & Dohme Limited","drug_phase":"marketed","molecular_target":"Follicle-stimulating hormone receptor","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"chorionic-gonadotrophin","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Choriogonadotropin","generic_name":"chorionic gonadotrophin","company_name":"Ferring","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"maltodextrin","indication_name":"headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aspartame/MSG Detox","generic_name":"MALTODEXTRIN","company_name":"Deseret Biologicals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with functional or anatomic asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with functional or anatomic asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with functional or anatomic asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cerebrospinal fluid shunts","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cerebrospinal fluid shunts","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cerebrospinal fluid shunts","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cochlear implants","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cochlear implants","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cochlear implants","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with alcohol use disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with alcohol use disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with alcohol use disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cerebrospinal fluid leaks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cerebrospinal fluid leaks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cerebrospinal fluid leaks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cochlear implantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"triptans","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptans","generic_name":"triptans","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin 5-HT1B/1D receptors","drug_class":"Selective serotonin receptor agonists","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"triptans","indication_name":"Cluster headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptans","generic_name":"triptans","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin 5-HT1B/1D receptors","drug_class":"Selective serotonin receptor agonists","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rsv-prefusion-f-protein-based-vaccine","indication_name":"Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSV prefusion F protein-based vaccine","generic_name":"rsv-prefusion-f-protein-based-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Respiratory syncytial virus fusion (F) protein","drug_class":"Viral protein subunit vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of advanced breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with functional or anatomic asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic heart disease, including congestive heart failure, coronary artery disease, or cardiac transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with alcohol use disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"incobotulinumtoxina","indication_name":"Horizontal forehead lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"adjuvant-letrozole-postmenopausal-women","indication_name":"Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adjuvant letrozole (postmenopausal women)","generic_name":"adjuvant-letrozole-postmenopausal-women","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"aromatase","drug_class":"aromatase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pilocarpine","indication_name":"Xerostomia Secondary to Radiation Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gonadorelin","indication_name":"Diagnostic Test for Gonadotropin Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fertagyl","generic_name":"GONADORELIN","company_name":"","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"gonadorelin","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelumab-msb0010718c","indication_name":"Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelumab (MSB0010718C)","generic_name":"avelumab-msb0010718c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"temoporfin","indication_name":"Neoplasm of head and neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscan","generic_name":"TEMOPORFIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"temoporfin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in postmenopausal women with disease progression following prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe axillary hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe axillary hidradenitis suppurativa in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae in adults 18 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 50 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 65 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or alcoholism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with functional or anatomic asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) after failure of prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) as a first-line treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Prevention of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"sumatriptan","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imitrex","generic_name":"SUMATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":80,"revenue":null,"mechanism":"Imitrex works by binding to serotonin receptors in the brain, specifically the 5-HT1D subtype, to constrict blood vessels and block pain pathways."},{"drug_id":"infigratinib","indication_name":"Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Truseltiq","generic_name":"INFIGRATINIB","company_name":"Helsinn Hlthcare","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"ganciclovir","indication_name":"Prevention of CMV Disease in Advanced HIV Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"flucytosine","indication_name":"Systemic Candidiasis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Systemic Cryptococcosis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Primary Hypogonadism due to Bilateral Torsion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Primary Hypogonadism due to Orchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pentobarbital","indication_name":"Tetanus Adjunct Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nembutal Sodium","generic_name":"PENTOBARBITAL","company_name":"Oak Pharms","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"pentobarbital","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metyrapone","indication_name":"Diagnostic Test for Secondary Adrenocortical Insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metopirone","generic_name":"METYRAPONE","company_name":"Esteve","drug_phase":"marketed","molecular_target":"Cytochrome P450 11B1, mitochondrial","drug_class":"Adrenal Steroid Synthesis Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Metopirone works by inhibiting the enzyme responsible for converting a precursor into cortisol, effectively reducing cortisol production."},{"drug_id":"probenecid","indication_name":"Adjunct Treatment to Inhibit Renal Drug Excretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Col-Probenecid","generic_name":"probenecid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 9","drug_class":"probenecid","quality_score":10,"revenue":null,"mechanism":"ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance."},{"drug_id":"trametinib","indication_name":"Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"azatadine","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azatidine","generic_name":"AZATADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"azatadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"technetium-tc-99m-tetrofosmin","indication_name":"Radionuclide myocardial perfusion study","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myoview","generic_name":"TECHNETIUM TC 99M TETROFOSMIN","company_name":"GE HealthCare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent","quality_score":40,"revenue":null,"mechanism":"Myoview works by accumulating in the heart muscle and emitting gamma rays that are detected by a scanner, allowing for visualization of blood flow."},{"drug_id":"darifenacin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enablex","generic_name":"DARIFENACIN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":80,"revenue":null,"mechanism":"Enablex works by blocking the action of a chemical called acetylcholine on the bladder muscle, which helps to relax the muscle and improve bladder control."},{"drug_id":"docetaxel","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"oxybutynin","indication_name":"Neurogenic bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ditropan Xl","generic_name":"OXYBUTYNIN","company_name":"Hisamitsu Pharmaceutical Co., Inc.","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":75,"revenue":null,"mechanism":"Oxybutynin works by blocking the action of a chemical called acetylcholine on the bladder muscle, reducing spasms and urgency."},{"drug_id":"amifostine","indication_name":"Prevention of Xerostomia Secondary to Radiation Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ethyol","generic_name":"AMIFOSTINE","company_name":"Cosette","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"amifostine","quality_score":75,"revenue":null,"mechanism":"Ethyol works by protecting the kidneys and salivary glands from damage caused by chemotherapy and radiation."},{"drug_id":"oxybutynin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ditropan Xl","generic_name":"OXYBUTYNIN","company_name":"Hisamitsu Pharmaceutical Co., Inc.","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":75,"revenue":null,"mechanism":"Oxybutynin works by blocking the action of a chemical called acetylcholine on the bladder muscle, reducing spasms and urgency."},{"drug_id":"palifermin","indication_name":"Mucositis following radiation therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kepivance","generic_name":"PALIFERMIN","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"Mucocutaneous Epithelial Cell Growth Factor [EPC]","quality_score":60,"revenue":null,"mechanism":"Kepivance works by binding to fibroblast growth factor receptor 2, stimulating the growth and proliferation of mucosal cells."},{"drug_id":"palifermin","indication_name":"Prevention of Radiation Therapy-Induced Mucositis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kepivance","generic_name":"PALIFERMIN","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"Mucocutaneous Epithelial Cell Growth Factor [EPC]","quality_score":60,"revenue":null,"mechanism":"Kepivance works by binding to fibroblast growth factor receptor 2, stimulating the growth and proliferation of mucosal cells."},{"drug_id":"tolbutamide","indication_name":"Diagnostic Test for Pancreatic Islet Cell Adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aglicid","generic_name":"TOLBUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"deferiprone","indication_name":"Iron overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ferriprox","generic_name":"DEFERIPRONE","company_name":"Chiesi","drug_phase":"marketed","molecular_target":"Deoxyhypusine hydroxylase","drug_class":"Iron Chelator [EPC]","quality_score":75,"revenue":null,"mechanism":"Ferriprox works by binding to iron in the body and removing it, thereby reducing iron overload."},{"drug_id":"levofolinic-acid","indication_name":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"Levofolinic acid","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"levofolinic-acid","indication_name":"Sulfadiazine Toxicity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"Levofolinic acid","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"levoleucovorin","indication_name":"Adjunct to Fluorouracil Treatment of Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"levoleucovorin","company_name":"Acrotech Biopharma","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":65,"revenue":null,"mechanism":"Fusilev works by bypassing the enzyme dihydrofolate reductase, allowing normal cell growth and DNA synthesis."},{"drug_id":"levoleucovorin","indication_name":"Sulfadiazine Toxicity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"levoleucovorin","company_name":"Acrotech Biopharma","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":65,"revenue":null,"mechanism":"Fusilev works by bypassing the enzyme dihydrofolate reductase, allowing normal cell growth and DNA synthesis."},{"drug_id":"zoledronic-acid","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"onivyde","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"onivyde","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":74,"revenue":null,"mechanism":"Camptosar works by inhibiting topoisomerase I, an enzyme that helps DNA replicate, causing DNA damage and cancer cell death."},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults and in combination with pembrolizumab in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Urothelial Carcinoma (UC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Urothelial Carcinoma (UC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Triple-Negative Breast Cancer (TNBC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Triple-Negative Breast Cancer (TNBC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"busulfan","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"mestranol","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norinyl 1+50 28-Day","generic_name":"MESTRANOL","company_name":"","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dipyridamole","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Persantine","generic_name":"DIPYRIDAMOLE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Persantine works by inhibiting platelet activation and aggregation by blocking the equilibrative nucleoside transporter 1."},{"drug_id":"degarelix","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Firmagon","generic_name":"degarelix","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist","quality_score":75,"revenue":null,"mechanism":"Firmagon works by blocking the action of gonadotropin-releasing hormone on the pituitary gland, which reduces testosterone production."},{"drug_id":"somapacitan","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"testosterone-undecanoate","indication_name":"Hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aveed","generic_name":"TESTOSTERONE UNDECANOATE","company_name":"Marius","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":70,"revenue":null,"mechanism":"Aveed works by binding to androgen receptors in the body, mimicking the effects of natural testosterone."},{"drug_id":"testosterone-undecanoate","indication_name":"Primary hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aveed","generic_name":"TESTOSTERONE UNDECANOATE","company_name":"Marius","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":70,"revenue":null,"mechanism":"Aveed works by binding to androgen receptors in the body, mimicking the effects of natural testosterone."},{"drug_id":"betamethasone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"ergotamine","indication_name":"Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migergot","generic_name":"ERGOTAMINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ergotamine","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migergot","generic_name":"ERGOTAMINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ergotamine","indication_name":"Vascular headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migergot","generic_name":"ERGOTAMINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"propofol","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprivan","generic_name":"Propofol","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"GABA A receptors","drug_class":"General anesthetic","quality_score":10,"revenue":null,"mechanism":"Propofol produces sedative/anesthetic effects by positive modulation of inhibitory GABA function through GABA A receptors."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"butorphanol","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stadol Preservative Free","generic_name":"BUTORPHANOL","company_name":"","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Opioid Agonist/Antagonist","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"triptorelin","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trelstar","generic_name":"triptorelin","company_name":"Verity","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":70,"revenue":null,"mechanism":"Trelstar works by binding to and activating the gonadotropin-releasing hormone receptor, which leads to a decrease in testosterone production."},{"drug_id":"clemastine","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavist","generic_name":"CLEMASTINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"clemastine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dextromethorphan","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delsym","generic_name":"dextromethorphan","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6","drug_class":"Antitussive (non-opioid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tetracaine","indication_name":"Administration of Corneal Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tetracaine Hydrochloride","generic_name":"TETRACAINE","company_name":"Alcon Labs","drug_phase":"marketed","molecular_target":"Sodium channel protein type 7 subunit alpha","drug_class":"Ester Local Anesthetic","quality_score":10,"revenue":null,"mechanism":"Tetracaine Hydrochloride works by blocking sodium channels in nerve cells to prevent pain signals from being transmitted."},{"drug_id":"doxycycline","indication_name":"Periodontitis Adjunct Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"byetta","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Byetta","generic_name":"Byetta","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Byetta works by activating the glucagon-like peptide 1 receptor, which helps regulate blood sugar levels."},{"drug_id":"chembl-chembl1200796","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"calcitonin","indication_name":"Hypercalcemia Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Osteobios","generic_name":"CALCITONIN","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"calcitonin receptor","drug_class":"Calcitonin [EPC]","quality_score":70,"revenue":null,"mechanism":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract."},{"drug_id":"ceftriaxone","indication_name":"Adult Gonococcal Conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methotrexate","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"pramlintide","indication_name":"Type 1 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symlin","generic_name":"PRAMLINTIDE","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"pramlintide","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symlin","generic_name":"PRAMLINTIDE","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"bepanthen","indication_name":"Toxicodendron radicans","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bepanthen","company_name":"RWTH Aachen University","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"firmagon","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Firmagon","company_name":"Centre Leon Berard","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zonegran","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zonegran","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludarabin","indication_name":"Low-grade B cell non-Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methotrexat","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lusedra","indication_name":"Sedation as Adjunct to Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lusedra","company_name":"Eisai Inc.","drug_phase":"phase_1","molecular_target":"GABA-A receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"opdualag","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"serevent","indication_name":"Adjunct Therapy to Achieve Long-term Asthma Control","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxycarbamide","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"andexanet","indication_name":"Direct acting anticoagulant adverse reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Andexanet","company_name":"Portola Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clemastin","indication_name":"Anaphylaxis Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clemastin","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"eligard","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eligard","company_name":"Astellas Pharma Europe Ltd.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gabapentine","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"gabapentine","company_name":"Dominik Irnich","drug_phase":"marketed","molecular_target":"Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epinephrin","indication_name":"Administration of Local Anesthetic Nerve Block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"elonva","indication_name":"Adolescent males with hypogonadotropic hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elonva","company_name":"University Medical Centre Ljubljana","drug_phase":"marketed","molecular_target":"Follicle-stimulating hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenylpropanol","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenylpropanol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adenosin","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adenosin","company_name":"University of Roma La Sapienza","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoladex","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoladex","company_name":"University of Michigan Rogel Cancer Center","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoladex","indication_name":"Endometrial Ablation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoladex","company_name":"University of Michigan Rogel Cancer Center","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"carbocaine","indication_name":"Administration of Local Anesthetic Nerve Block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbocaine","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"carbocaine","indication_name":"Administration of Regional Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbocaine","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Low-grade B cell non-Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"simponi","indication_name":"Nonradiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Simponi","company_name":"Alvotech Swiss AG","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bydureon","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bydureon","company_name":"Phoenix VA Health Care System","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor, Glucagon-like peptide 1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rabeprazol","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"retigabine","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Retigabine","company_name":"Bausch Health Americas, Inc.","drug_phase":"discontinued","molecular_target":"Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"humira","indication_name":"Hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfex","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"sialanar","indication_name":"Vagal Reflex Bradycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sialanar","company_name":"Proveca Pharma Limited","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tarceva","indication_name":"Adenocarcinoma of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tarceva","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"AarF domain-containing protein kinase 4, Acyl-CoA dehydrogenase family member 11, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"proxymetacaine","indication_name":"Administration of Corneal Anesthesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proxymetacaine","company_name":"Medical University of Silesia","drug_phase":"phase_1","molecular_target":"Amine oxidase [flavin-containing] A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Xerostomia Secondary to Radiation Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Adrenal cortical hypofunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Adrenogenital disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Primary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Severe adrenal insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amchafibrin","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amchafibrin","company_name":"Fundación Pública Andaluza Progreso y Salud","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"somatropine","indication_name":"Prader-Willi syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"somatropine","company_name":"Sanofi","drug_phase":"phase_3","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"somatropine","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"somatropine","company_name":"Sanofi","drug_phase":"phase_3","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"erbitux","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tasigna","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"transamin","indication_name":"Female hypogonadism syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"transamin","company_name":"Erzincan Military Hospital","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"welchol","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Welchol","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bromocriptin","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"desferrioxamine","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"desferrioxamine","company_name":"Brigham and Women's Hospital","drug_phase":"phase_3","molecular_target":"Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"triptoreline","indication_name":"Advanced Prostatic Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Triptoreline","company_name":"Universitaire Ziekenhuizen KU Leuven","drug_phase":"phase_2","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enbrel","indication_name":"Nonradiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enbrel","company_name":"LG Life Sciences","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lexiscan","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lexiscan","company_name":"Medical University of South Carolina","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"oxytrol","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oxytrol","company_name":"Jewish General Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"oxytrol","indication_name":"Neurogenic bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oxytrol","company_name":"Jewish General Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Multiple endocrine adenomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"photofrin","indication_name":"Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Photofrin","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"photofrin","indication_name":"High Grade Dysplasia associated with Barrett's Esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Photofrin","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naproxen","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aleve","generic_name":"naproxen","company_name":"Generic (originally Syntex)","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","drug_class":"NSAID","quality_score":null,"revenue":null,"mechanism":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects."},{"drug_id":"naproxen","indication_name":"Sinus headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aleve","generic_name":"naproxen","company_name":"Generic (originally Syntex)","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","drug_class":"NSAID","quality_score":null,"revenue":null,"mechanism":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects."},{"drug_id":"ondansetron","indication_name":"Prevention of Radiation-Induced Nausea and Vomiting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zofran","generic_name":"ondansetron","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1","drug_class":"5-HT3 receptor antagonist (antiemetic)","quality_score":null,"revenue":null,"mechanism":"Selective 5-HT3 receptor antagonist that blocks serotonin-mediated nausea and vomiting signals in the CTZ and vagal afferents."},{"drug_id":"mitotane","indication_name":"Carcinoma in situ of adrenal cortex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lysodren","generic_name":"MITOTANE","company_name":"Esteve","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"mitotane","quality_score":70,"revenue":null,"mechanism":"Lysodren works by inhibiting the production of cortisol and aldosterone in the adrenal cortex."},{"drug_id":"capecitabine","indication_name":"Perioperative treatment of locally advanced rectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Treatment of advanced or metastatic breast cancer (with docetaxel)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Adjuvant treatment of pancreatic adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"capecitabine","indication_name":"Treatment of advanced or metastatic breast cancer (single agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"prednisone","indication_name":"Primary or secondary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Secondary thrombocytopenia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Leukemias and lymphomas in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"somatrogon","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"somatrogon","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone."},{"drug_id":"hyoscyamine","indication_name":"Neurogenic Bladder and Bowel Disturbances","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"torisel","indication_name":"Advanced renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"Temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"temsirolimus","quality_score":10,"revenue":null,"mechanism":"Temsirolimus is an inhibitor of mTOR, a protein that controls cell division."},{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer with capecitabine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer as a single agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"fludrocortisone","indication_name":"Primary and Secondary Adrenocortical Insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"fludrocortisone","company_name":"Generic","drug_phase":"marketed","molecular_target":"Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Mineralocorticoid","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"fludrocortisone","indication_name":"Salt-Losing Adrenogenital Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"fludrocortisone","company_name":"Generic","drug_phase":"marketed","molecular_target":"Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Mineralocorticoid","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"same","indication_name":"Sadness Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMe","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Methyltransferases","drug_class":"Vitamin B12 [EPC]","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"depo-testosterone","indication_name":"Primary Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"depo-testosterone","indication_name":"Hypogonadotropic Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fragmin","indication_name":"Extended Treatment of Symptomatic VTE in Adult Patients with Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"same","indication_name":"Occasional Headache Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMe","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Methyltransferases","drug_class":"Vitamin B12 [EPC]","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"tetracosactide","indication_name":"Adrenocortical insufficiency screening","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortrosyn","generic_name":"tetracosactide","company_name":"Amphastar Pharms Inc","drug_phase":"marketed","molecular_target":"Melanocortin receptor 4","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"toviaz","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toviaz","generic_name":"Fesoterodine Fumarate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"fesoterodine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"droxidopa","indication_name":"Orthostatic dizziness, lightheadedness, or the feeling of about to black out due to nOH","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Northera","generic_name":"DROXIDOPA","company_name":"Lundbeck Na Ltd","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Catecholamine","quality_score":10,"revenue":null,"mechanism":"Northera works by increasing the levels of certain neurotransmitters in the brain, such as norepinephrine, to help regulate blood pressure and movement."},{"drug_id":"elapegademase","indication_name":"Adenosine deaminase severe combined immune deficiency (ADA-SCID)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."},{"drug_id":"lyrica","indication_name":"Adjunctive therapy for partial-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"testosterone","indication_name":"Primary Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"testosterone","indication_name":"Hypogonadotropic Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Disseminated adenocarcinoma of the stomach or pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Palliative treatment for disseminated adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lamotrigine","indication_name":"Epilepsy - Adjunctive Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"mer","indication_name":"Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mer Detox 6019","generic_name":"mer","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"anastrozole","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arimidex","generic_name":"anastrozole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase enzyme","drug_class":"Aromatase inhibitor","quality_score":68,"revenue":null,"mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer."},{"drug_id":"anastrozole","indication_name":"First-line treatment of advanced breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arimidex","generic_name":"anastrozole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase enzyme","drug_class":"Aromatase inhibitor","quality_score":68,"revenue":null,"mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer."},{"drug_id":"anastrozole","indication_name":"Second-line treatment of advanced breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arimidex","generic_name":"anastrozole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase enzyme","drug_class":"Aromatase inhibitor","quality_score":68,"revenue":null,"mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer."},{"drug_id":"diuretic","indication_name":"Headache relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diuretic","company_name":"Reprieve Cardiovascular, Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Calculi Dissolution Agent [EPC]","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"cisatracurium-besylate","indication_name":"Skeletal muscle relaxation during surgery in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimbex","generic_name":"Cisatracurium Besylate","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Acetylcholine receptor","drug_class":"Nondepolarizing Neuromuscular Blocker","quality_score":10,"revenue":null,"mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction."},{"drug_id":"cisatracurium-besylate","indication_name":"Mechanical ventilation in the ICU in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimbex","generic_name":"Cisatracurium Besylate","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Acetylcholine receptor","drug_class":"Nondepolarizing Neuromuscular Blocker","quality_score":10,"revenue":null,"mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction."},{"drug_id":"foslevodopa","indication_name":"Motor fluctuations in advanced Parkinson’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSLEVODOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease."},{"drug_id":"cholic-acid","indication_name":"Adjunctive Treatment of Peroxisomal Disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cholbam","generic_name":"CHOLIC ACID","company_name":"Mirum","drug_phase":"marketed","molecular_target":"G-protein coupled bile acid receptor 1","drug_class":"Bile Acid [EPC]","quality_score":53,"revenue":null,"mechanism":"Cholbam works by binding to the G-protein coupled bile acid receptor 1, which helps regulate bile acid levels in the body."},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Parkinsonism Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Levodopa Adjuvant Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cisatracurium-besylate","indication_name":"Tracheal intubation in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimbex","generic_name":"Cisatracurium Besylate","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Acetylcholine receptor","drug_class":"Nondepolarizing Neuromuscular Blocker","quality_score":10,"revenue":null,"mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction."},{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"sunitinib","indication_name":"Advanced Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sunitinib","indication_name":"Adjuvant Treatment of High-Risk Recurrent RCC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"dabigatran-etexilate","indication_name":"Treatment of DVT and PE in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"apap","indication_name":"Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated","generic_name":"APAP","company_name":"HF Acquisition Co LLC, DBA HealthFirst","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"pegfilgrastim-pbbk","indication_name":"Increase survival in radiation exposure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"FYLNETRA","generic_name":"PEGFILGRASTIM-PBBK","company_name":"KASHIV BIOSCIENCES LLC","drug_phase":"marketed","molecular_target":"specific cell surface receptors","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":"Pegfilgrastim binds to specific cell surface receptors on hematopoietic cells, stimulating their proliferation, differentiation, and functional activation."},{"drug_id":"dabigatran-etexilate","indication_name":"Reduction of DVT and PE recurrence in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"trastuzumab-anns","indication_name":"Adjuvant Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Primary or secondary adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Acute adrenocortical insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"undecanoate","indication_name":"Primary Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"undecanoate","indication_name":"Hypogonadotropic Hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"bimekizumab-bkzx","indication_name":"Active non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BIMZELX","generic_name":"BIMEKIZUMAB-BKZX","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","drug_class":"","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-aqvh","indication_name":"Hidradenitis Suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"YUSIMRY","generic_name":"ADALIMUMAB-AQVH","company_name":"COHERUS BIOSCIENCES INC","drug_phase":"marketed","molecular_target":"","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bimekizumab-bkzx","indication_name":"Moderate to severe hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BIMZELX","generic_name":"BIMEKIZUMAB-BKZX","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","drug_class":"","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Secondary thrombocytopenia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Leukemias and lymphomas in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Diagnostic testing of adrenocortical hyperfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Adult Growth Hormone Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"filgrastim-txid","indication_name":"Radiation Exposure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NYPOZI","generic_name":"FILGRASTIM-TXID","company_name":"TANVEX BIOPHARMA USA INC","drug_phase":"marketed","molecular_target":"Specific cell surface receptors on hematopoietic cells","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":50,"revenue":null,"mechanism":"G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function."},{"drug_id":"chembl-chembl1444","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1444","indication_name":"Extended adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"somapacitan-beco","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan-beco","indication_name":"Replacement of endogenous GH in GHD adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1444","indication_name":"First-line treatment of advanced breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1444","indication_name":"Second-line treatment of advanced breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1219","indication_name":"Helicobacter pylori Eradication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RABEPRAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1219","indication_name":"Treatment of Symptomatic GERD in Adolescents","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RABEPRAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in pediatric and adult acute lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"solifenacin-succinate","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SOLIFENACIN SUCCINATE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic receptors","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Solifenacin blocks muscarinic receptors, reducing urinary bladder smooth muscle contractions."},{"drug_id":"lurasidone","indication_name":"Bipolar Depression (Adjunctive Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Cervical dystonia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Blepharospasm in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Moderate to severe horizontal forehead lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in adult acute nonlymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Adjuvant Treatment of Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Advanced Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"mitoxantrone","indication_name":"Advanced Hormone-Refractory Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Corneal injury from chemical, radiation, or thermal burns","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3301587","indication_name":"Locally Advanced or Metastatic BTC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."},{"drug_id":"chembl-chembl3301587","indication_name":"Advanced or Recurrent Endometrial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."},{"drug_id":"chembl-chembl3301587","indication_name":"Muscle Invasive Bladder Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."},{"drug_id":"pemetrexed-disodium","indication_name":"Locally Advanced or Metastatic Non-Squamous NSCLC - Initial Treatment with Cisplatin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"pilocarpine","indication_name":"Dry mouth due to radiotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mafenide","indication_name":"Adjunctive therapy for second- and third-degree burns","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfamylon","generic_name":"MAFENIDE","company_name":"Rising","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 12","drug_class":"Methylated Sulfonamide Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triprolidine","indication_name":"Headache relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actidil","generic_name":"TRIPROLIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"triprolidine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"sevabertinib","indication_name":"Locally advanced or metastatic non-squamous NSCLC with HER2 TKD mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SEVABERTINIB","company_name":"","drug_phase":"marketed","molecular_target":"HER2, EGFR","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Sevabertinib inhibits HER2 and EGFR phosphorylation, blocking downstream signaling and cancer cell proliferation."},{"drug_id":"trastuzumab-and-hyaluronidase-oysk","indication_name":"Adjuvant Treatment of HER2-Overexpressing Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trastuzumab and Hyaluronidase-oysk","company_name":"Adrienne G. Waks","drug_phase":"marketed","molecular_target":"HER2","drug_class":"Endoglycosidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits HER2-overexpressing tumor cell proliferation and mediates ADCC, while hyaluronidase increases subcutaneous permeability for better drug absorption."},{"drug_id":"neo-bladder-construct","indication_name":"Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Low-Grade Glioma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3833373","indication_name":"Advanced Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"chembl-chembl2103875","indication_name":"Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1946170","indication_name":"Locally Advanced, Unresectable or Metastatic GIST","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"REGORAFENIB","company_name":"","drug_phase":"marketed","molecular_target":"RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Regorafenib inhibits multiple kinases involved in oncogenesis, angiogenesis, metastasis, and tumor immunity."},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Low-Grade Glioma in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl894","indication_name":"Prevention of Seasonal Affective Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUPROPION","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"viloxazine-hydrochloride","indication_name":"Treatment of ADHD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VILOXAZINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"sodium-sulfate","indication_name":"Migraine headache pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"sodium-sulfate","indication_name":"Headache pain with nausea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"sodium-sulfate","indication_name":"Headache due to simple nervous tension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"dextromethorphan-hydrobromide","indication_name":"Headache Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROMETHORPHAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Expectorant [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"pyrilamine","indication_name":"Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PYRILAMINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"somapacitan","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"hydroxyzine-pamoate","indication_name":"Adjunct in organic disease states with anxiety","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYZINE PAMOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"somapacitan","indication_name":"Growth hormone deficiency in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"salmeterol","indication_name":"Asthma Not Adequately Controlled","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta2-adrenoceptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Fluticasone propionate reduces inflammation, while salmeterol relaxes bronchial muscles and inhibits mediator release."},{"drug_id":"chembl-chembl3301589","indication_name":"Neoadjuvant and Adjuvant Treatment of MIBC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl359744","indication_name":"Adjuvant Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Transitional Cell Bladder Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl1751","indication_name":"Heart Failure in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DIGOXIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cardiac Glycoside [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1751","indication_name":"Atrial Fibrillation in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DIGOXIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cardiac Glycoside [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl1201577","indication_name":"Locally or regionally advanced SCCHN","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"fremanezumab-vfrm","indication_name":"Preventive treatment of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fremanezumab-Vfrm","company_name":"Manhattan Beach Orthodontics","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide (CGRP)","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Fremanezumab-vfrm binds to CGRP and blocks its interaction with the receptor."},{"drug_id":"chembl-chembl941","indication_name":"Adjuvant Treatment of Kit+ GIST","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl4297830","indication_name":"Growth failure due to inadequate growth hormone secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SOMATROGON","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200641","indication_name":"Tracheal Intubation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISATRACURIUM BESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"cholinergic receptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Cisatracurium besylate blocks neuromuscular transmission by competitively binding to cholinergic receptors and antagonizing acetylcholine."},{"drug_id":"tezepelumab","indication_name":"Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"TEZEPELUMAB","company_name":"AstraZeneca / Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl11359","indication_name":"Advanced Bladder Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISPLATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Platinum-based Drug [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"drug-abatacept","indication_name":"Hidradenitis Suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"mouth-rinse","indication_name":"Control of plaque leading to bleeding gums","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"mouth rinse","company_name":"Ministry of Higher Education, Malaysia","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"phenolphthalein","indication_name":"Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phthalin","generic_name":"PHENOLPHTHALEIN","company_name":"","drug_phase":"marketed","molecular_target":"Thymidylate synthase, Thymidylate synthase","drug_class":"phenolphthalein","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"drug-abatacept","indication_name":"Hidradenitis Suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Adjuvant Treatment of Early Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Extended Adjuvant Treatment of Early Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"First-Line Treatment of Advanced Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Second-Line Treatment of Advanced Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"dextroamphetamine-sulfate","indication_name":"Attention Deficit Hyperactivity Disorder (ADHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROAMPHETAMINE SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"darifenacin-hydrobromide","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DARIFENACIN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"intravesical-solution","indication_name":"BCG-refractory CIS of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravesical Solution","company_name":"Ankara Training and Research Hospital","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"celery-seed","indication_name":"Bladder stones","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Celery Seed","company_name":"University of Guadalajara","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pyrilamine-maleate","indication_name":"Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PYRILAMINE MALEATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"fluid-balance","indication_name":"Headaches","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluid balance","company_name":"Brugmann University Hospital","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"datopotamab-deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated NSCLC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DATOPOTAMAB DERUXTECAN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"Advanced ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"Adjuvant breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"doxycycline","indication_name":"Uncomplicated urethral, endocervical, or rectal infections in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3545110","indication_name":"Adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIBOCICLIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545110","indication_name":"Initial endocrine-based therapy for advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIBOCICLIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"testosterone-enantate","indication_name":"Male hypogonadism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyosted (Autoinjector)","generic_name":"testosterone enantate","company_name":"Endo","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caduet","indication_name":"Coronary Artery Disease (CAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"caduet","indication_name":"Angiographically Documented CAD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"bacillus-calmette-guerin","indication_name":"Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"magnesium-salicylate","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Magan","generic_name":"magnesium salicylate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium salicylate","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"diazepam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valium","generic_name":"diazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hyoscyamine","indication_name":"Gastrointestinal Radiography Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"hyoscyamine","indication_name":"Sinus bradycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"dexibuprofen","indication_name":"Headache disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXIBUPROFEN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"dexibuprofen","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"cosentyx","indication_name":"Non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cosentyx","company_name":"Janssen Research & Development, LLC","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"calcitonin-pork-natural","indication_name":"Hypercalcemia Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcitonin Pig","generic_name":"calcitonin (pork natural)","company_name":"","drug_phase":"unknown","molecular_target":"Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1","drug_class":"calcitonin (pork natural)","quality_score":null,"revenue":null,"mechanism":"Calcitonin Pig works by mimicking a hormone in the body that helps regulate calcium levels."},{"drug_id":"abilify","indication_name":"Depression Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"keppra","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Head and neck squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"prevnar-20","indication_name":"Immunocompromised adults (CLL, HIV, autoimmune)","indication_type":"pipeline","phase":"phase_3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"},{"drug_id":"olaparib-oral-product","indication_name":"Muscle-invasive bladder cancer","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"olaparib-oral-product","indication_name":"Advanced prostate adenocarcinoma with neuroendocrine differentiation","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"olaparib-oral-product","indication_name":"Advanced BRCA-mutated or HDR-deficient breast cancer","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"olaparib-oral-product","indication_name":"Platinum-resistant/refractory high-grade serous ovarian cancer","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"obi-999","indication_name":"Advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OBI-999","company_name":"OBI Pharma, Inc","drug_phase":"discontinued","molecular_target":"Globo H (globoside carbohydrate antigen)","drug_class":"Antibody-drug conjugate (ADC)","quality_score":null,"revenue":null,"mechanism":"OBI-999 is an antibody-drug conjugate targeting Globo H carbohydrate antigen on cancer cells to deliver cytotoxic payload."},{"drug_id":"pf-06940434","indication_name":"Squamous Cell Carcinoma of the Head and Neck","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06940434","generic_name":"pf-06940434","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2","quality_score":null,"revenue":null,"mechanism":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2"},{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."},{"drug_id":"pf-07329640","indication_name":"Advanced or Metastatic Solid Tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07329640","generic_name":"pf-07329640","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Data not available","drug_class":"Data not available","quality_score":null,"revenue":null,"mechanism":"Mechanism of action not disclosed in available data."},{"drug_id":"bevacizumab-eu","indication_name":"Advanced Non-squamous NSCLC","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab-EU","generic_name":"bevacizumab-eu","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we","quality_score":0,"revenue":null,"mechanism":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we"},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Advanced solid tumors (RP-3467 + olaparib combination)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"High-grade serous ovarian cancer (idetrexed + olaparib)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"olaparib-oral-product","indication_name":"BRCA1/2-mutated and HRD-positive advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."},{"drug_id":"pd-0332991","indication_name":"Advanced Hepatocellular Carcinoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"nitroglycerin","indication_name":"Subcutaneous nitroglycerin to facilitate trans-radial access","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"oral-anticoagulant","indication_name":"Secondary stroke prevention in older adults","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."},{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."},{"drug_id":"pf-07062119","indication_name":"Advanced or metastatic gastrointestinal tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07062119","generic_name":"pf-07062119","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Undisclosed molecular target (pathway inhibitor in gastrointestinal cancer)","drug_class":"Selective pathway inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07062119 is a selective inhibitor targeting a key molecular pathway in gastrointestinal cancer cell proliferation."},{"drug_id":"cosyntropin","indication_name":"Post-dural puncture headache","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COSYNTROPIN","company_name":"","drug_phase":"marketed","molecular_target":"MC2 receptor","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cosyntropin","indication_name":"Adrenal suppression","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COSYNTROPIN","company_name":"","drug_phase":"marketed","molecular_target":"MC2 receptor","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"torsemide","indication_name":"Heart failure with overactive bladder","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."},{"drug_id":"pf-07265028","indication_name":"Advanced Solid Tumors","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07265028","generic_name":"pf-07265028","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-07265028 will be administered orally","quality_score":null,"revenue":null,"mechanism":"PF-07265028 will be administered orally"},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Small-cell lung cancer (olaparib + low-dose radiotherapy)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."}],"offLabel":[],"totalMarketed":2269,"totalPipeline":24},"trials":{"data":[{"nct_id":"NCT06289075","title":"PrognostICate- Study:Prognostication of ICU- and Ventilator- Days Over the Next Years Until 2040","phase":"","overall_status":"RECRUITING","enrollment_count":10000000,"lead_sponsor_name":"University Hospital of Cologne","has_results":false},{"nct_id":"NCT06801158","title":"Adverse Drug Reactions to Cancer Therapies in Patients with Depression: Insights from VigiBase","phase":"","overall_status":"COMPLETED","enrollment_count":8804863,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT03903094","title":"A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden","phase":"","overall_status":"COMPLETED","enrollment_count":6295279,"lead_sponsor_name":"Astellas Pharma Singapore Pte. Ltd.","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06406998","title":"Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD","phase":"","overall_status":"RECRUITING","enrollment_count":5461222,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05126992","title":"EU Secondary Data Post-Authorisation Safety Study of AZD1222","phase":"","overall_status":"COMPLETED","enrollment_count":5321930,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02285868","title":"ATI Evidence-based Guide Investigating Clinical Services","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000000,"lead_sponsor_name":"ATI Holdings, LLC","has_results":false},{"nct_id":"NCT04856436","title":"Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy","phase":"","overall_status":"COMPLETED","enrollment_count":3094227,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT02695121","title":"Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":2133575,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05234333","title":"COVID-19 Vaccines Associated Malaise","phase":"","overall_status":"COMPLETED","enrollment_count":1534706,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06824896","title":"A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ","phase":"","overall_status":"COMPLETED","enrollment_count":1322084,"lead_sponsor_name":"Xiamen Innovax Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04740645","title":"NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden","phase":"","overall_status":"COMPLETED","enrollment_count":1099551,"lead_sponsor_name":"Ferring Pharmaceuticals","has_results":false},{"nct_id":"NCT03776435","title":"CT Carcinogenic Risk in Patients With Appendicitis","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT04551248","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT03482232","title":"Consequences of Doing What Should Not be Done in Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":750000,"lead_sponsor_name":"Universidad Miguel Hernandez de Elche","has_results":false},{"nct_id":"NCT01077817","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","phase":"","overall_status":"COMPLETED","enrollment_count":684815,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT04996732","title":"Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06440447","title":"EXploring Patterns of Use and Effects of Adult Day Programs to Improve Trajectories of Continuing CarE","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500000,"lead_sponsor_name":"York University","has_results":false},{"nct_id":"NCT07117045","title":"Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06420453","title":"How Long Can Labor Last? Person Centred Care During Labor to Increase Safety for Women and Newborn","phase":"","overall_status":"COMPLETED","enrollment_count":300000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04579822","title":"Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy","phase":"","overall_status":"UNKNOWN","enrollment_count":300000,"lead_sponsor_name":"Sungkyunkwan University","has_results":false},{"nct_id":"NCT03585348","title":"Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal","phase":"","overall_status":"COMPLETED","enrollment_count":265537,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT06722040","title":"Effect and Safety of a Pediatric Triage Track on Hospital Visits and at the Public Medical Helpline 1813, Capital Region, Denmark","phase":"","overall_status":"COMPLETED","enrollment_count":244000,"lead_sponsor_name":"Emergency Medical Services, Capital Region, Denmark","has_results":false},{"nct_id":"NCT05471882","title":"Predicting Neuromuscular Recovery in Surgical Patients Using Machine Learning","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240000,"lead_sponsor_name":"University Hospital Ulm","has_results":false},{"nct_id":"NCT05366621","title":"Post-fracture Medication and Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":216155,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT04426994","title":"Hypomagnesemia Associated With Proton-Pump Inhibitor Use","phase":"","overall_status":"COMPLETED","enrollment_count":211672,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT05418218","title":"International Headache Registry Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07093684","title":"Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05380570","title":"Epidemiological Study of Korean Radiation Workers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":196379,"lead_sponsor_name":"Korea Institute of Radiological & Medical Sciences","has_results":false},{"nct_id":"NCT03335644","title":"The NutriNet-Santé Study","phase":"","overall_status":"RECRUITING","enrollment_count":170000,"lead_sponsor_name":"University of Paris 13","has_results":false},{"nct_id":"NCT04496544","title":"Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study)","phase":"","overall_status":"COMPLETED","enrollment_count":168553,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT05745129","title":"Applying Artificial Intelligence in Developing Personalized and Sustainable Healthcare for Spinal Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":165000,"lead_sponsor_name":"Oslo Metropolitan University","has_results":false},{"nct_id":"NCT02668549","title":"Cross-Sectional Study to Define and Validate \"Doctor/Pharmacy Shopping\" as Outcomes Suggestive of Abuse and/or Addiction","phase":"","overall_status":"COMPLETED","enrollment_count":164923,"lead_sponsor_name":"Member Companies of the Opioid PMR Consortium","has_results":false},{"nct_id":"NCT06115200","title":"Norwegian Adult Mental Health Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT06180447","title":"Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Sun Xin","has_results":false},{"nct_id":"NCT00410475","title":"Cancer Risk in X-Ray Technologists: Second Survey","phase":"","overall_status":"COMPLETED","enrollment_count":146022,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04579237","title":"Development and Evaluation of Techniques for Computer Aided Detection and Diagnosis From Existing Radiologic Images","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":144625,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT05934214","title":"EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database","phase":"","overall_status":"COMPLETED","enrollment_count":141630,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT06245759","title":"The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":120000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT03575247","title":"The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":111804,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT03585400","title":"Validation of the REPS Prediction Tool","phase":"","overall_status":"COMPLETED","enrollment_count":101510,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT03357302","title":"Risk Factors Associated With the Global Burden of Disease in Reunion Island and Comparison With Mainland France and Indian Ocean Countries","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Réunion","has_results":false},{"nct_id":"NCT04504162","title":"Monitoring and Risk Prediction of Iatrogenic Sedative Hypnotics Addiction in a Shanghai Psychiatric Hospital","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT03762837","title":"Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04279470","title":"Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT07514377","title":"JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"National Research Institute for Family Planning, China","has_results":false},{"nct_id":"NCT05628467","title":"Association Between Antidepressant Use and Falls in Older Adults: Analysis of the World Health Organization Global Database","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT03653156","title":"China Cognition and Aging Study","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT06528236","title":"Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}